Eclosion2 is an opportunity to invest in a unique portfolio of companies with outstanding medical and financial upside potential.
Eclosion2 assembles into a new vehicle the experience, the track record and the portfolio of companies established by Eclosion, a successful launch platform for disruptive biotech companies.
Breakthrough therapeutics starting clinical trials in 2010, addressing large unmet medical needs
Strong network and privileged access to prestigious Universities and Academic Institutions
Hands-on scientific testing at Eclosion's state-of-the-art facilities to select future winners
Experienced management team that has demonstrated its ability to deliver exceptional returns
Printer-friendly version
Send to friend